Barbara Ann DeBuono

Saluda Medical Appoints Laureen DeBuono to Board of Directors

Retrieved on: 
Tuesday, October 4, 2022
University School, Record, The Lancet, Audit committee, Stanford University, Randomized controlled trial, JAMA Neurology, RCT, Bachelor of Arts in Clinical Psychology, CEO, Barbara Ann DeBuono, Adoption, Low back pain, Invivo Wines, SCS, Neurology, Evoke, Therapy, Safety, Duke University, CFO, PMA, New York University School of Law, Webbed toes, Lists of diseases, Awareness, Pharmaceutical industry, Management

ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors.

Key Points: 
  • ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors.
  • "Laureen's extensive background across operational and strategic levels at both public and private companies, as well as her director level experience, speaks for itself," said Jim Schuermann, president and CEO of Saluda Medical.
  • DeBuono is a seasoned executive who has served in a multitude of senior executive level roles at various private and public companies across the healthcare and consumer sectors.
  • Currently, she is a managing partner at FLG Partners, focusing on interim CEO, CFO, and board advisory services, as well as executive coaching.

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

Retrieved on: 
Monday, September 13, 2021
Nasdaq, Health, U.S. Securities and Exchange Commission, Board of directors, Investment, Therapy, Security (finance), SAN, R, Board, Novo Holdings A/S, Forward-looking statement, IPO, Silicon, Invivo Wines, Hand, Patient, Research, CFO, Private Securities Litigation Reform Act, LP, Risk, Safety, General counsel, Growth, Talat, COVID-19, Barbara Ann DeBuono, GLOBE, Goal, Pharmaceutical industry, Management, Animal

SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Rani Therapeutics or Rani) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
  • In July 2021, Rani Therapeutics commenced an initial public offering (IPO) of its Class A common stock and began trading on the Nasdaq Global Market under the ticker symbol RANI.
  • In June 2021, Rani announced the appointment of Talat Imran as Chief Executive Officer.
  • In June 2021, Rani announced the appointments of Jean-Luc Butel and Laureen DeBuono to its Board of Directors.